07.05.2024
Acino signs an exclusive license agreement with Supernus in Latin America
M8 Pharmaceuticals, an Acino company (‘M8’) announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc....
M8 Pharmaceuticals, an Acino company (‘M8’) announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc....
Acino has been recognised as the top employer among pharmaceutical companies in Ukraine. This ranking is the result of a...
Joel Barlan has been appointed as Head of the LATAM region. Mexico City will now serve as a regional hub...
We are pleased to announce the appointment of Samir El Nasharty as Chief Operations Officer and member of Acino’s Executive...
M8 Pharmaceuticals, an Acino company (“M8”) and SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, are collaborating to bring an...
We are proud to announce the appointment of Ingrid Eberle as Chief Compliance and Sustainability Officer, effective 1 March 2024....
The agreement focuses on the distribution of orphan drugs developed for patients with conditions such as rheumatoid arthritis, cryopyrin-associated periodic...
For the third consecutive year, Acino South Africa has been awarded with the Top Employer certification. The Top Employer certification is one...
With nearly 300 new employees on board, Acino will enhance its presence in Latin America and strengthen its business through...